These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3416311)

  • 1. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage.
    Willson JK; Fischer PH; Tutsch K; Alberti D; Simon K; Hamilton RD; Bruggink J; Koeller JM; Tormey DC; Earhart RH
    Cancer Res; 1988 Oct; 48(19):5585-90. PubMed ID: 3416311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion.
    Fischer PH; Willson JK; Risueno C; Tutsch K; Bruggink J; Ranhosky A; Trump DL
    Cancer Res; 1988 Oct; 48(19):5591-6. PubMed ID: 3416312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
    Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.
    Willson JK; Fischer PH; Remick SC; Tutsch KD; Grem JL; Nieting L; Alberti D; Bruggink J; Trump DL
    Cancer Res; 1989 Apr; 49(7):1866-70. PubMed ID: 2924325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
    Remick SC; Grem JL; Fischer PH; Tutsch KD; Alberti DB; Nieting LM; Tombes MB; Bruggink J; Willson JK; Trump DL
    Cancer Res; 1990 May; 50(9):2667-72. PubMed ID: 2328492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole.
    Fischer PH; Pamukcu R; Bittner G; Willson JK
    Cancer Res; 1984 Aug; 44(8):3355-9. PubMed ID: 6744269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
    Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
    Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
    Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion.
    Earhart RH; Koeller JM; Davis TE; Borden EC; McGovren JP; Davis HL; Tormey DC
    Cancer Treat Rep; 1983; 67(7-8):683-92. PubMed ID: 6871883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies.
    Morgan RJ; Newman EM; Sowers L; Scanlon K; Harrison J; Akman S; Leong L; Margolin K; Niland J; Raschko J; Somlo G; Carroll M; Chow W; Tetef M; Hamasaki V; Yen Y; Doroshow JH
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):459-64. PubMed ID: 12695856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
    Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
    Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
    Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture.
    Williams MG; Earhart RH; Bailey H; McGovren JP
    Cancer Res; 1990 Sep; 50(17):5475-80. PubMed ID: 2386952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
    Lyass O; Hubert A; Gabizon AA
    Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.